文献速递产科母胎医学

利用19至23周评估的超声和血管生成标志物辅助后续子痫前期诊断

Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2022-03-09

这项前瞻性队列研究纳入英格兰2家产科医院的40,241例单胎妊娠,在19至23周进行常规评估(病史、超声估计胎儿体重、子宫动脉搏动指数多普勒及血清胎盘生长因子),比较不同子痫前期定义对不良结局的检出率。结果显示,2018年国际妊娠期高血压研究学会母胎因素加胎盘生长因子定义(较传统定义)最能识别发生不良结局的孕妇。

要点

  • 2018年ISSHP母胎因素加胎盘生长因子定义子痫前期发生率为3.8%,传统定义为2.6%。
  • 该定义较传统定义对严重高血压检出率70.6% vs 52.8%(P<.001)。
  • 该定义较传统定义对围产期死亡或严重疾病检出率84.6% vs 69.5%(P=.004)。

核心结论

  • 19至23周评估中的子宫胎盘功能障碍标准(包括胎盘生长因子)可用于评估后来疑似子痫前期的孕妇,以最佳识别有不良结局风险的妊娠。

研究设计与样本

  • 前瞻性队列研究,纳入英格兰2家产科医院2011年10月至2020年3月的40,241例单胎妊娠,在19至23周进行常规评估。

主要发现

  • 子痫前期发生率随定义不同,从传统定义的2.6%和美国妇产科医师学会定义的3.0%至2018年ISSHP母胎因素加胎盘生长因子定义的3.8%。
  • 2018年ISSHP母胎因素加胎盘生长因子定义(vs 传统定义)检出率:严重高血压70.6% vs 52.8%(P<.001),严重孕产妇疾病100% vs 87.5%(P=.027),围产期死亡或严重疾病84.6% vs 69.5%(P=.004),新生儿重症监护病房住院≥48小时76.6% vs 63.2%(P=.0002),出生体重<第3百分位81.3% vs 61.9%(P<.0001)。
  • 从美国妇产科医师学会定义到2018年ISSHP母胎因素加胎盘生长因子定义,检出率改善:严重高血压11.4%(P=.003),围产期死亡或严重疾病10.6%(P=.03),新生儿重症监护病房住院≥48小时8.6%(P=.01),出生体重<第3百分位16.2%(P<.001)。
  • 从2018年ISSHP母胎因素定义到加胎盘生长因子定义,出生体重<第3百分位胎儿检出改善7.0%(P=.01),其余无改善:严重高血压1.7%(P=.33),严重孕产妇疾病0%,围产期死亡或严重疾病4.0%(P=.20),新生儿重症监护病房住院≥48小时3.2%(P=.17)。

关键数值与推荐

  • 子痫前期定义包括:传统定义(妊娠≥20周新发蛋白尿);2013年美国妇产科医师学会定义;2018年ISSHP母体因素定义;2018年ISSHP母胎因素定义(基于19 0/7至23 6/7周超声,估计胎儿体重<第3百分位或估计胎儿体重第3至第10百分位且子宫动脉搏动指数>第95百分位);2021年ISSHP母胎因素加胎盘生长因子定义(异常胎盘生长因子定义为估计胎儿体重<第5百分位)。
  • 采用卡方检验比较检出率,P<.05为有统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A definition of preeclampsia that incorporates the assessment of maternal, fetal, and uteroplacental status would optimize the identification of pregnancies at risk of complications at term gestational age. This definition would include "carrying forward" angiogenic test results from 35 to 36 weeks of gestation to term gestational age. Would this approach still be useful if testing is performed earlier or at a routine midgestation scan and the result is used to inform the diagnosis of preeclampsia that developed thereafter? OBJECTIVE: This study aimed to evaluate whether fetoplacental assessment at a 19- to 23-week scan could be "carried forward" to contribute to the classification of preeclampsia and improve the detection of women and fetuses at risk of adverse outcomes associated with hypertension. STUDY DESIGN: In this prospective cohort study of singleton pregnancies at 2 maternity hospitals in England (October 2011 to March 2020), women attending a routine hospital visit at 19 to 23 weeks of gestation underwent an assessment that included history, ultrasonographic estimated fetal weight, Doppler measurements of the pulsatility index in uterine arteries, and serum placental growth factor. Preeclampsia was defined according to various definitions: (1) traditional, based on new-onset proteinuria at ≥20 weeks of gestation; (2) 2013 American College of Obstetricians and Gynecologists; (3) 2018 International Society for the Study of Hypertension in Pregnancy maternal factor; (4) 2018 International Society for the Study of Hypertension in Pregnancy maternal-fetal factor (death or growth restriction), based on ultrasound scans at the 19 0/7 to 23 6/7 week of gestation (an estimated fetal weight of <3rd percentile or estimated fetal weight between the 3rd and 10th percentiles with a uterine artery pulsatility index of >95th percentile); and (5) 2021 International Society for the Study of Hypertension in Pregnancy maternal-fetal factor plus placental growth factor (with abnormal placental growth factor defined as an estimated fetal weight of <5th percentile for gestational age). The detection rates for outcomes of interest (ie, severe maternal hypertension, major maternal morbidity, perinatal mortality or major neonatal morbidity, neonatal intensive care unit admission ≥48 hours, and birthweight of <3rd percentile) ascertained by health record review were compared using the chi-square test. A P value of <.05 was considered statistically significant. RESULTS: Among 40,241 singleton pregnancies, preeclampsia incidence varied by definition, from lows of 2.6% (traditional) and 3.0% (American College of Obstetricians and Gynecologists) to a high of 3.8% (International Society for the Study of Hypertension in Pregnancy maternal-fetal factor plus placental growth factor). The International Society for the Study of Hypertension in Pregnancy maternal-fetal factor plus placental growth factor definition (vs the traditional) best identified women who developed adverse outcomes: severe hypertension (detection rate: 70.6% vs 52.8%; P<.001), major maternal morbidity (detection rate: 100% vs 87.5%; P=.027), perinatal mortality or major morbidity (detection rate: 84.6% vs 69.5%; P=.004), neonatal intensive care unit admission ≥48 hours (detection rate: 76.6% vs 63.2%;, P=.0002), and birthweight of <3rd percentile (detection rate: 81.3% vs 61.9%; P<.0001]. The detection rates improved, going from the American College of Obstetricians and Gynecologists definition to the International Society for the Study of Hypertension in Pregnancy maternal-fetal factor plus placental growth factor definition, for severe hypertension (11.4%; P=.003), perinatal mortality or major morbidity (10.6%; P=.03), neonatal intensive care unit admission ≥48 hours (8.6%; P=.01), and birthweight of <3rd percentile (16.2%; P<.001). However, going from the International Society for the Study of Hypertension in Pregnancy maternal-fetal factor definition to the International Society for the Study of Hypertension in Pregnancy maternal-fetal factor plus placental growth factor definition, the detection of fetuses with a birthweight of <3rd percentile improved by 7.0% (P=.01), but no other improvement was seen for severe hypertension (1.7%; P=.33), major maternal morbidity (0%), perinatal mortality or major morbidity (4.0%; P=.20), and neonatal intensive care unit admission ≥48 hours (3.2%; P=.17). CONCLUSION: The criteria for uteroplacental dysfunction (including placental growth factor) from the 19- to 23-week assessment can be used in the assessment of women who are later suspected of having PE, to best identify pregnancies at risk of adverse outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lai J, Syngelaki A, Nicolaides KH, et al. Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia. Am J Obstet Gynecol. 2022. PMID: 35276067. doi:10.1016/j.ajog.2022.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。